Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel

Janick Weberpals; Spyros Roumpanis; Yael Barer; Sharon Ehrlich; Nikki Jessop; Rosetta Pedotti; Adi Vaknin-Dembinsky; Livnat Brill; Gabriel Chodick; Erwan Muros Le Rouzic

doi:https://doi.org/10.1016/j.msard.2022.104153

Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel

Janick Weberpals, Spyros Roumpanis, Yael Barer, Sharon Ehrlich, Nikki Jessop, Rosetta Pedotti, Adi Vaknin-Dembinsky, Livnat Brill, Gabriel Chodick, Erwan Muros Le Rouzic

Research output: Contribution to journal › Letter › peer-review

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused challenges in the management of patients living with multiple sclerosis (PLwMS). We investigated the occurrence and severity of COVID-19 infection post-vaccination among PLwMS treated with ocrelizumab and enrolled in the Maccabi Health Services (MHS) (n = 289) or followed at the Hadassah Medical Center (HMC) (n = 80) in Israel. Most patients were fully vaccinated (MHS n = 218; HMC n = 76) and confirmed infection post-vaccination was low (3.7% and 2.6%, respectively). MHS: infection was more severe (hospitalization/intensive care unit/death) in non-vaccinated (33.3%) vs vaccinated patients (25%). HMC: one vaccinated patient required hospitalization with COVID-19 vs two unvaccinated patients. These data from two Israel cohorts suggest that occurrence of COVID-19 after mRNA vaccination is low and limited in severity.

Original language	English
Article number	104153
Journal	Multiple Sclerosis and Related Disorders
Volume	68
DOIs	https://doi.org/10.1016/j.msard.2022.104153
State	Published - Dec 2022
Externally published	Yes

All Science Journal Classification (ASJC) codes

Neurology
Clinical Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1016/j.msard.2022.104153

Cite this

Weberpals, J., Roumpanis, S., Barer, Y., Ehrlich, S., Jessop, N., Pedotti, R., Vaknin-Dembinsky, A., Brill, L., Chodick, G., & Rouzic, E. M. L. (2022). Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel. Multiple Sclerosis and Related Disorders, 68, Article 104153. https://doi.org/10.1016/j.msard.2022.104153

@article{fe378687e84a4eb3ad5f2ebae2648d20,

title = "Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel",

abstract = "The coronavirus disease 2019 (COVID-19) pandemic caused challenges in the management of patients living with multiple sclerosis (PLwMS). We investigated the occurrence and severity of COVID-19 infection post-vaccination among PLwMS treated with ocrelizumab and enrolled in the Maccabi Health Services (MHS) (n = 289) or followed at the Hadassah Medical Center (HMC) (n = 80) in Israel. Most patients were fully vaccinated (MHS n = 218; HMC n = 76) and confirmed infection post-vaccination was low (3.7% and 2.6%, respectively). MHS: infection was more severe (hospitalization/intensive care unit/death) in non-vaccinated (33.3%) vs vaccinated patients (25%). HMC: one vaccinated patient required hospitalization with COVID-19 vs two unvaccinated patients. These data from two Israel cohorts suggest that occurrence of COVID-19 after mRNA vaccination is low and limited in severity.",

author = "Janick Weberpals and Spyros Roumpanis and Yael Barer and Sharon Ehrlich and Nikki Jessop and Rosetta Pedotti and Adi Vaknin-Dembinsky and Livnat Brill and Gabriel Chodick and Rouzic, {Erwan Muros Le}",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = dec,

doi = "https://doi.org/10.1016/j.msard.2022.104153",

language = "الإنجليزيّة",

volume = "68",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier B.V.",

}

Weberpals, J, Roumpanis, S, Barer, Y, Ehrlich, S, Jessop, N, Pedotti, R, Vaknin-Dembinsky, A, Brill, L, Chodick, G & Rouzic, EML 2022, 'Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel', Multiple Sclerosis and Related Disorders, vol. 68, 104153. https://doi.org/10.1016/j.msard.2022.104153

TY - JOUR

T1 - Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods

T2 - Insights from Israel

AU - Weberpals, Janick

AU - Roumpanis, Spyros

AU - Barer, Yael

AU - Ehrlich, Sharon

AU - Jessop, Nikki

AU - Pedotti, Rosetta

AU - Vaknin-Dembinsky, Adi

AU - Brill, Livnat

AU - Chodick, Gabriel

AU - Rouzic, Erwan Muros Le

PY - 2022/12

Y1 - 2022/12

N2 - The coronavirus disease 2019 (COVID-19) pandemic caused challenges in the management of patients living with multiple sclerosis (PLwMS). We investigated the occurrence and severity of COVID-19 infection post-vaccination among PLwMS treated with ocrelizumab and enrolled in the Maccabi Health Services (MHS) (n = 289) or followed at the Hadassah Medical Center (HMC) (n = 80) in Israel. Most patients were fully vaccinated (MHS n = 218; HMC n = 76) and confirmed infection post-vaccination was low (3.7% and 2.6%, respectively). MHS: infection was more severe (hospitalization/intensive care unit/death) in non-vaccinated (33.3%) vs vaccinated patients (25%). HMC: one vaccinated patient required hospitalization with COVID-19 vs two unvaccinated patients. These data from two Israel cohorts suggest that occurrence of COVID-19 after mRNA vaccination is low and limited in severity.

AB - The coronavirus disease 2019 (COVID-19) pandemic caused challenges in the management of patients living with multiple sclerosis (PLwMS). We investigated the occurrence and severity of COVID-19 infection post-vaccination among PLwMS treated with ocrelizumab and enrolled in the Maccabi Health Services (MHS) (n = 289) or followed at the Hadassah Medical Center (HMC) (n = 80) in Israel. Most patients were fully vaccinated (MHS n = 218; HMC n = 76) and confirmed infection post-vaccination was low (3.7% and 2.6%, respectively). MHS: infection was more severe (hospitalization/intensive care unit/death) in non-vaccinated (33.3%) vs vaccinated patients (25%). HMC: one vaccinated patient required hospitalization with COVID-19 vs two unvaccinated patients. These data from two Israel cohorts suggest that occurrence of COVID-19 after mRNA vaccination is low and limited in severity.

UR - http://www.scopus.com/inward/record.url?scp=85137283210&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.msard.2022.104153

DO - https://doi.org/10.1016/j.msard.2022.104153

M3 - رسالة

C2 - 36081277

SN - 2211-0348

VL - 68

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

M1 - 104153

ER -

Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this